cancer.duke.edu/btc  
The Preston Robert Tisch Brain Tumor Center at Duke

Science Paves the Way for Hope

Science is the engine behind the Preston Robert Tisch Brain Tumor Center at Duke. Our researchers and physicians are passionate about understanding the "how" and "why" of brain tumors. Scientists are developing new, more effective techniques for surgery, chemotherapy, and radiation therapy. Research is devoted not only to providing the most effective treatment, but also to improving the quality of life for patients and their loved ones.

—Darell D. Bigner, MD, PhD
Director

Our researchers and physicians have pioneered remarkable advances in surgery and treatment including the following:

  • Use of monoclonal antibodies to carry cancer-killing treatment to the primary tumor site without harming healthy tissue
  • Injections of immunotoxins directly into the brain to attack tumor cells that surgeons cannot remove
  • Identification of genes that are over-multiplying in brain tumors to help determine why certain cells resist therapy
  • Use of Ritalin for child and adolescent attention difficulties after brain tumor therapy

Every day, we complete another piece of the puzzle. For more information on the latest scientific advances...

 


Printer Friendly Page Send this Story to a Friend
AACR Team Science Award

AACR Team Science Award

The American Association for Cancer Research (AACR) awarded the Eighth Annual AACR Team Science Award to the Duke University/Johns Hopkins University/National Cancer Institute (NCI) Malignant Brain Tumor Team at the AACR Annual Meeting 2014, held in San Diego, Calif., April 5-9.

The AACR Team Science Award recognizes an outstanding interdisciplinary research team for its innovative and meritorious scientific work that has advanced or will likely advance cancer research, detection, diagnosis, prevention or treatment.

Read more...

 

Research Grant Announced

Yiping He, PhD

NCCN Names Young Investigator Award
Yiping He, PhD, Assistant Professor of Pathology, has won the National Comprehensive Cancer Network (NCC) Foundation Young Investigator Awards Grant for his proposed research. Dr. He won for a proposal on “Genetic approaches for analyzing the role of aberrant MLL2 in tumorigenesis.” The award provides total support of $150,000 over a two-year period starting in September 2013.  Dr. He will also get a travel/housing grant to attend and present data at the NCCN annual conference.